<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860781</url>
  </required_header>
  <id_info>
    <org_study_id>R092670-SCH-4008</org_study_id>
    <nct_id>NCT01860781</nct_id>
  </id_info>
  <brief_title>The Effect of Paliperidone Palmitate in Schizophrenia</brief_title>
  <acronym>sustenna</acronym>
  <official_title>The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of effectiveness of paliperidone palmitate within
      three different group of schizophrenia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to examine the effectiveness of paliperidone
      palmitate after changing from other antipsychotics. This study design is a Prospective
      Naturalistic Case Series Study. The effectiveness of paliperidone would be compared within
      three different groups of schizophrenia. Investigators would also assess the safety during 24
      weeks follow up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGI-S,I: Clinical Global Impression-Severity, Improvement</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS: Positive and Negative Syndrome Scale</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRS: Clinician Rating Scale</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KDAI-10: Korean Drug Attitude Inventory-10</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SWN: Subjective Well-being Under Neuroleptic Treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DIEPSS: Drug-Induced ExtraPyramidal Symptoms Sclae</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>injection site pain -VAS: Visual Analog Scale</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUNSERS: Liverpool University Neuroleptic Side Effect Rating Scale</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>paliperidone palmitate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paliperidone palmitate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone palmitate</intervention_name>
    <description>paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)</description>
    <arm_group_label>paliperidone palmitate</arm_group_label>
    <other_name>paliperidone palmitate(sustenna)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 ~ 65

          -  Patient with schizophrenia according to DSM-IV criteria

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study.

          -  PANSSS total score &lt;120

          -  each Score of disorganized thought, paranoia hallucinatory behavior, abnormal tbought
             contests &lt; 16

          -  three different groups ( other antipsychotics refractory schizophrenia patitents :
             CGI&gt; 4 chronic akathisia : DIEPSS overall severity &gt;1, at least 1 month lasting
             symptoms poor compliance schizophrenia : CRS &lt;3)

          -  Competent patient who is manage to answer the questionnaires.

          -  In case of female at child-bearing age, consent to use appropriate contraceptive
             methods(oral pill, contraceptive injection, intrauterine device, double barrier method
             and contraceptive patch) during entire duration of this study.

        Exclusion Criteria:

          -  No history of antipsychotics prescription

          -  History of NMS(Neuroleptic malignant syndrome)

          -  Allergic reaction or hypersensitive reaction of risperidone or paliperidone ER

          -  clozapine medication within 1 month before screening

          -  SSRI, MAOI, TCA medication within 2 months

          -  Lithium, valproic acid, carbamazepine, topiramate, lamotrigine medication starting
             within 2 months

          -  patient who is supposed to be impossible to participate to this study due to clinical
             risk of suicide or aggressive behavior based on clinician's opinion

          -  current or previous history of drug depedence according to DSM-IV

          -  Pregnant or breast-feeding female patient

          -  Significant biochemical or hematological abnormality or abnormal finding of
             urinalysis, based on clinician's opinion

          -  history of cardiac disease, which is related to QT prolongation(sick sinus, complete
             AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia)

          -  History of participating to other investigational drug trial within 1month prior to
             screening

          -  Investigator or employee at clinical trial center, personnel related to investigator
             or trial center on this or other study, or family of employee or investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Min Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>December 6, 2015</last_update_submitted>
  <last_update_submitted_qc>December 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Min Ahn</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Injection</keyword>
  <keyword>Switch</keyword>
  <keyword>Paliperidone</keyword>
  <keyword>refractory, chronic akathisia, poor complianc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

